Humacyte, Inc.
HUMA
$2.14
-$0.175-7.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 222.71% | 16.59% | -50.81% | -149.55% | 13.72% |
| Total Depreciation and Amortization | 2.29% | -1.36% | -0.98% | -10.29% | -13.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -908.95% | -554.41% | 169.52% | 1,936.90% | -53.79% |
| Change in Net Operating Assets | -105.24% | -179.88% | -51.58% | 217.56% | -2,830.82% |
| Cash from Operations | -4.59% | -39.48% | -76.11% | 5.80% | -46.70% |
| Capital Expenditure | 41.69% | 58.00% | -89.45% | 62.06% | 66.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 41.69% | 58.00% | -89.45% | -111.34% | 66.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -13.93% | -14.46% | -14.21% | 98.01% | -14.20% |
| Issuance of Common Stock | 9.28% | 19,726.88% | 400.00% | 728.42% | 36,368.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 454.20% | -101.59% | -- |
| Cash from Financing | -25.57% | 15,325.67% | 211.13% | -107.76% | 15,453.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.91% | 224.70% | -61.19% | -46.61% | 273.53% |